Search for a trial

A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA

This study has been transitioned to CTIS with ID 2023-503793-20-00 check the CTIS register for the current data. The main purpose of this study is to learn whether asundexian works better than placebo at reducing ischemic strokes in participants who…

A Two Part Phase IIa/b Multicentre, Randomised, Double-Blind,
Placebo-Controlled, Parallel Group Dose-ranging Study to Assess
Efficacy, Safety, and Tolerability of the Combination of
Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy
Versus Placebo in Participants with Cirrhosis with Features of
Portal Hypertension

This study has been transitioned to CTIS with ID 2023-505405-17-00 check the CTIS register for the current data. The main objective of this Phase IIa/b study is to demonstrate the effectof zibotentan on HVPG, and that dapagliflozin can mitigate…

Surgery and exercise versus exercise only for chronic patellofemoral pain syndrome: a randomised controlled trial.

Zie het onderzoeksprotocol 2: "Objectives".

Interventional, randomized, double-blind, parallel-group, placebo-controlled study of add-on eptinezumab treatment to brief educational intervention for the preventive treatment of migraine in patients with dual diagnosis of migraine and Medication Overuse Headache

This study has been transitioned to CTIS with ID 2024-510729-24-00 check the CTIS register for the current data. Primary Objective• To evaluate the efficacy of eptinezumab as add-on to BI for the prevention of migraine and treatment of MOHSecondary…

Tirzepatide Study of Renal Function in People with Overweight or Obesity and
Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney
Hypoxia in Relation to Fatty Kidney Disease using Multiparametric Magnetic
Resonance Imaging (TREASURE-CKD)

This study has been transitioned to CTIS with ID 2023-506082-60-00 check the CTIS register for the current data. The objective of this study is to investigate the mechanism(s) of action of tirzepatide in the kidney, in participants who are…

3D Virtual Surgery In an Orthopaedic-trauma Network
(3D ViSION trial)
A randomised-controlled study initiated by the department of Trauma Surgery, Orthopaedic Surgery and the 3D lab of the University Medical Center Groningen

To assess the following research questions: 1. Does the use of 3D virtual preoperative planning of surgery improve functional outcome as measured by Patient-Reported Outcome in comparison to conventional surgery (using conventional radiographs and/…

A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

This study has been transitioned to CTIS with ID 2023-505277-32-00 check the CTIS register for the current data. The primary objective of this study is to evaluate whether the addition of epcoritamab to 6 cycles of standard R-CHOP followed by 2…

Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity

This study has been transitioned to CTIS with ID 2023-506929-11-00 check the CTIS register for the current data. Primary To confirm superiority on body weight reduction of CagriSema 2.4 mg/2.4 mg versus placebo as adjuncts to reduced-calorie diet…

A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy

This study has been transitioned to CTIS with ID 2023-510019-20-00 check the CTIS register for the current data. Primary:To evaluate the efficacy of depemokimab 200 mg SC every 26 weeks compared with mepolizumab 300 mg SC every 4 weeks in…

A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, ParallelGroup Study of the Efficacy and Safety of Losmapimod in Treating Patients with Facioscapulohumeral Muscular Dystrophy (REACH)

This study has been transitioned to CTIS with ID 2024-512737-33-00 check the CTIS register for the current data. Primary Objective:Part A:To evaluate the efficacy of losmapimod for the treatment of FSHD by demonstrating slowing of disease…

Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): A Double-blind, Randomized, Placebo-controlled Study

This study has been transitioned to CTIS with ID 2024-516124-34-00 check the CTIS register for the current data. Primary Objective:• To evaluate the effects of withdrawal of tiratricol treatment (placebo group) on serum total triiodothyronine (T3)…

The effect of the Progressive Goal Attainment Program (PGAP) on cognitions and perceptions and workparticipation of workers with a chronic disease in the Netherlands

To study whether PGAP is effective in changing cognitions and perceptions and increasing work participation of workers with a chronic diseae in the Netherlands and to study whether implementing PGAP is feasible in the Netherlands.

Online nurse-assisted eye-screening in home healthcare; implementation study and economic evaluation, from an individual, healthcare and socio-political perspective [iSCREEN-study]

Cost-utility and cost-effectiveness of eye-screening in home healthcare in reducing eye complaints from a societal perspective and its health consequences will be investigated over 1 year. A cluster randomized controlled trial (RCT), including an…

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING)

This study has been transitioned to CTIS with ID 2023-504277-20-00 check the CTIS register for the current data. The aim of this global Phase III study is to investigate the use of tezepelumab as a treatment for patients with EoE. This study will…

A multicenter, international, randomized, active comparator-controlled, double-blind, doubledummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor Asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke

This study has been transitioned to CTIS with ID 2023-503794-38-00 check the CTIS register for the current data. - To demonstrate that asundexian is superior (at least non-inferior) when compared with apixaban for prevention of stroke and systemic…

A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide

This study has been transitioned to CTIS with ID 2023-503444-13-00 check the CTIS register for the current data. The primary objective of this study is to compare the efficacy of teclistamab monotherapy (Arm A) with that of an investigator*s choice…

A Phase 3 Randomized Study Comparing Talquetamab in Combination with Daratumumab (SC) and Pomalidomide (Tal-DP) or Talquetamab (SC) in combination with Daratumumab SC (Tal-D) versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

This study has been transitioned to CTIS with ID 2023-503467-41-00 check the CTIS register for the current data. The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and…

A comparison between Qutenza and duloxetine for the treatment of painful chemotherapy-induced peripheral neuropathy (QULOX): a pragmatic randomized controlled trial

The primary objective is to determine whether in patients with CIPN pain, treatment with Qutenza has the same effect as treatment with duloxetine

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OF PTC857 IN ADULT SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (CARDINALS)

This study has been transitioned to CTIS with ID 2023-510317-26-00 check the CTIS register for the current data. To evaluate the efficacy of PTC857 in reducing disease progression in subjects with amyotrophic lateral sclerosis (ALS)

What is the optimal antithrombotic strategy in patients with atrial fibrillation having acute coronary syndrome or undergoing percutaneous coronary intervention?

This study has been transitioned to CTIS with ID 2022-502140-13-00 check the CTIS register for the current data. 1. To compare bleeding risk (i.e. safety) with DAPT compared to standard therapy during the first 30 days following PCI/ACS in patients…